Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $272

Benzinga · 2d ago
Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $248 to $272.